Table 3.
Hemophagocytic lymphohistiocytosis (HLH) in COVID-19 disease.
| Study | Reference number | Country | Patient number | Age (years), median (range) | Sex | HSscore, median (range) | Treatment response |
|---|---|---|---|---|---|---|---|
| Debliquis et al. | 90 | France | 1 | 63 | 1M | 207 | Deceased without specific treatment |
| Dimopoulos et al. | 91 | Greece and the Netherlands | 8 | 68 (51, 84) | 7M1F | 175 (171, 188) | Decreased HScore after anakinra but 3 (38%) of them eventually deceased |
| Faguer et al. | 92 | France | 1 | 51 | 1M | 253 | Decreased HScore after tocilizumab |
| Hakim et al. | 93 | USA | 1 | 37 | 1M | 204 | Decreased HScore after tocilizumab but eventually deceased on ventilator |
| Prilutskiy et al. | 88 | USA | 1 | 72 | 1M | 217 | Hemophagocytosis found post-mortem despite anakinra |
| Wood et al. | 94 | UK | 3 | N.A. | N.A. | N.A. | Decreased HScore after tocilizumab but then contracting a bacterial pneumonia |
COVID-19, the coronavirus disease 2019; N.A., not available.